Market Overview:
The global recombinant human EGF market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for recombinant human EGF for scientific research and medical drug applications. Additionally, the growing population and rising income levels are also contributing to the growth of this market.
Product Definition:
A recombinant human EGF is a protein that is derived from genetic engineering techniques. It has the same structure and function as naturally occurring human EGF. Recombinant human EGF can be used to treat medical conditions that result from a deficiency or lack of this hormone, such as skin ulcers, wounds, and radiation burns.
≥98% SDS-PAGE:
Recombinant human erythropoietin (EGF) is a glycoprotein hormone that controls the rate of red blood cell production.
95%-98% SDS-PAGE:
The Recombinant Human EGF market is expected to witness significant growth over the forecast period. The primary factor that can be attributed to this growth is the rising incidences of various degenerative diseases such as rheumatoid arthritis, osteoporosis and cancer which in turn leads to increased demand for therapeutics.
Application Insights:
On the basis of application, the global market is segmented into scientific research, medical drug and others. The other applications include food & beverages and cosmetics. In 2017, medical drug accounted for the largest share in terms of revenue as well as volume. This can be attributed to increasing usage of recombinant human EGF in various indications such as cancer treatment and wound healing which are currently treated with high-quality proteins derived from animal sources such as bovine or porcine sources.
EGF produced via microbial fermentation has a number of advantages including low cost compared to its counterpart derived from animals; it also reduces any potential risk associated with disease transmission byproducts that may be caused due to genetic modification techniques used during conventional protein production methods involving mammalian cell culture (such as growth hormones). These aforementioned factors are expected to drive demand over the forecast period thereby driving growth for this segment over the coming years.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of pharmaceutical and biopharmaceutical companies, which are engaged in the development and commercialization of products based on recombinant human EGF, is one of the major factors contributing to its largest share. Moreover, increasing investments by these companies for R&D activities related to therapeutic proteins is also expected to contribute toward its largest share over the forecast period.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to increasing government initiatives for promoting biotechnology industry in this region coupled with growing awareness among people regarding potential benefits associated with rHEG therapy over conventional therapies such as bone marrow transplantation and stem cell therapy. These aforementioned factors are expected favorably impact regional market growth during future years.
Growth Factors:
- Increasing demand for anti-aging products
- Growing awareness about the benefits of EGF
- Rising number of research and development activities for recombinant human EGF
- Increasing investments by key players in the market
- Technological advancements
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Human EGF Market Research Report
By Type
≥98% SDS-PAGE, 95%-98% SDS-PAGE, <95% SDS-PAGE
By Application
Scientific Research, Medical Drug, Others
By Companies
FUJIFILM Irvine Scientific, PeproTech, Inc, R&D Systems (Bio-Techne), Miltenyi Biotec, Thermo Fisher Scientific, Abcam PLC, BioLegend Way, STEMCELL Technologies, Eurofins DiscoverX, RayBiotech, Inc, Prospec-Tany, Tonbo Biosciences, EnQuire Bio, ScienCell Research Laboratories, BioVision, Inc, Abm Inc, Cell Guidance Systems, Creative BioMart, Sino Biological, Cell Sciences, Axol Bioscience
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Human EGF Market Report Segments:
The global Recombinant Human EGF market is segmented on the basis of:
Types
≥98% SDS-PAGE, 95%-98% SDS-PAGE, <95% SDS-PAGE
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Scientific Research, Medical Drug, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- FUJIFILM Irvine Scientific
- PeproTech, Inc
- R&D Systems (Bio-Techne)
- Miltenyi Biotec
- Thermo Fisher Scientific
- Abcam PLC
- BioLegend Way
- STEMCELL Technologies
- Eurofins DiscoverX
- RayBiotech, Inc
- Prospec-Tany
- Tonbo Biosciences
- EnQuire Bio
- ScienCell Research Laboratories
- BioVision, Inc
- Abm Inc
- Cell Guidance Systems
- Creative BioMart
- Sino Biological
- Cell Sciences
- Axol Bioscience
Highlights of The Recombinant Human EGF Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ≥98% SDS-PAGE
- 95%-98% SDS-PAGE
- <95% SDS-PAGE
- By Application:
- Scientific Research
- Medical Drug
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Human EGF Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant human epidermal growth factor (rhEGF) is a protein that is made in a laboratory by recombining the DNA of two different types of cells. The first type of cell is usually taken from the skin or blood, and the second type of cell helps to make rhEGF.
Some of the key players operating in the recombinant human egf market are FUJIFILM Irvine Scientific, PeproTech, Inc, R&D Systems (Bio-Techne), Miltenyi Biotec, Thermo Fisher Scientific, Abcam PLC, BioLegend Way, STEMCELL Technologies, Eurofins DiscoverX, RayBiotech, Inc, Prospec-Tany, Tonbo Biosciences, EnQuire Bio, ScienCell Research Laboratories, BioVision, Inc, Abm Inc, Cell Guidance Systems, Creative BioMart, Sino Biological, Cell Sciences, Axol Bioscience.
The recombinant human egf market is expected to grow at a compound annual growth rate of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Recombinant Human EGF Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Recombinant Human EGF Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Recombinant Human EGF Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Recombinant Human EGF Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Recombinant Human EGF Market Size & Forecast, 2018-2028
4.5.1 Recombinant Human EGF Market Size and Y-o-Y Growth
4.5.2 Recombinant Human EGF Market Absolute $ Opportunity
Chapter 5 Global Recombinant Human EGF Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Recombinant Human EGF Market Size Forecast by Type
5.2.1 ≥98% SDS-PAGE
5.2.2 95%-98% SDS-PAGE
5.2.3 <95% SDS-PAGE
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Recombinant Human EGF Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Recombinant Human EGF Market Size Forecast by Applications
6.2.1 Scientific Research
6.2.2 Medical Drug
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Recombinant Human EGF Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Recombinant Human EGF Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Recombinant Human EGF Analysis and Forecast
9.1 Introduction
9.2 North America Recombinant Human EGF Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Recombinant Human EGF Market Size Forecast by Type
9.6.1 ≥98% SDS-PAGE
9.6.2 95%-98% SDS-PAGE
9.6.3 <95% SDS-PAGE
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Recombinant Human EGF Market Size Forecast by Applications
9.10.1 Scientific Research
9.10.2 Medical Drug
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Recombinant Human EGF Analysis and Forecast
10.1 Introduction
10.2 Europe Recombinant Human EGF Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Recombinant Human EGF Market Size Forecast by Type
10.6.1 ≥98% SDS-PAGE
10.6.2 95%-98% SDS-PAGE
10.6.3 <95% SDS-PAGE
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Recombinant Human EGF Market Size Forecast by Applications
10.10.1 Scientific Research
10.10.2 Medical Drug
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Recombinant Human EGF Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Recombinant Human EGF Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Recombinant Human EGF Market Size Forecast by Type
11.6.1 ≥98% SDS-PAGE
11.6.2 95%-98% SDS-PAGE
11.6.3 <95% SDS-PAGE
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Recombinant Human EGF Market Size Forecast by Applications
11.10.1 Scientific Research
11.10.2 Medical Drug
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Recombinant Human EGF Analysis and Forecast
12.1 Introduction
12.2 Latin America Recombinant Human EGF Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Recombinant Human EGF Market Size Forecast by Type
12.6.1 ≥98% SDS-PAGE
12.6.2 95%-98% SDS-PAGE
12.6.3 <95% SDS-PAGE
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Recombinant Human EGF Market Size Forecast by Applications
12.10.1 Scientific Research
12.10.2 Medical Drug
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Recombinant Human EGF Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Recombinant Human EGF Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Recombinant Human EGF Market Size Forecast by Type
13.6.1 ≥98% SDS-PAGE
13.6.2 95%-98% SDS-PAGE
13.6.3 <95% SDS-PAGE
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Recombinant Human EGF Market Size Forecast by Applications
13.10.1 Scientific Research
13.10.2 Medical Drug
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Recombinant Human EGF Market: Competitive Dashboard
14.2 Global Recombinant Human EGF Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 FUJIFILM Irvine Scientific
14.3.2 PeproTech, Inc
14.3.3 R&D Systems (Bio-Techne)
14.3.4 Miltenyi Biotec
14.3.5 Thermo Fisher Scientific
14.3.6 Abcam PLC
14.3.7 BioLegend Way
14.3.8 STEMCELL Technologies
14.3.9 Eurofins DiscoverX
14.3.10 RayBiotech, Inc
14.3.11 Prospec-Tany
14.3.12 Tonbo Biosciences
14.3.13 EnQuire Bio
14.3.14 ScienCell Research Laboratories
14.3.15 BioVision, Inc
14.3.16 Abm Inc
14.3.17 Cell Guidance Systems
14.3.18 Creative BioMart
14.3.19 Sino Biological
14.3.20 Cell Sciences
14.3.21 Axol Bioscience
